Favipiravir co-administration with lopinavir-ritonavir increased favipiravir clearance by twofold in COVID-19 patients
Trial shows favipiravir and lopinavir-ritonavir do not stop COVID-19
This Phase 2a randomized, double-blind, 2x2 factorial placebo-controlled trial evaluated favipiravir and lopinavir-ritonavir in patients wit…
A new trial reveals that combining favipiravir with lopinavir-ritonavir did not show antiviral activity against the virus in patients with C…
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes
What helps hospitalized COVID-19 patients survive? A new model offers clues
This cohort study of 711 hospitalized subjects with coronavirus evaluated antiviral, antiretroviral, and immunosuppressive treatments.
When COVID-19 hits hard, doctors need better tools to predict who might get worse.